Search - tctmd.com

Displaying 81 - 100 of 170

Sort: Relevancy | Date

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

New Estimates of Bleeding Risks May Help CVD Prevention

Todd Neale

June 27, 2018

News Daily News

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

Todd Neale

June 21, 2018

News Daily News

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Caitlin E. Cox

June 19, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Daily News

Among African Americans in Need of LDL Lowering: Less Statin Use, More Distrust of Doctors

Michael O'Riordan

June 13, 2018

Podcast Heart Sounds

Lower BP Targets Can Save Over 300,000 Lives a Year, Analysis Suggests

L.A. McKeown

May 23, 2018

News Conference News EuroPCR 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Shelley Wood

May 22, 2018

News Daily News

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

L.A. McKeown

May 16, 2018

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

L.A. McKeown

May 15, 2018

News Conference News EAS 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Yael L. Maxwell

May 14, 2018

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

News Daily News

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

Michael O'Riordan

May 10, 2018

News Conference News EAS 2018

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Yael L. Maxwell

May 08, 2018

News Conference News EAS 2018

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Yael L. Maxwell

May 07, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Advertisement

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

New Review Probes Possibility of CVD Prevention Without Aspirin

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

New Estimates of Bleeding Risks May Help CVD Prevention

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Among African Americans in Need of LDL Lowering: Less Statin Use, More Distrust of Doctors

Top Stories in Cardiology: May 2018

Lower BP Targets Can Save Over 300,000 Lives a Year, Analysis Suggests

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content